REN and chronic kidney disease: Of those who were ineligible for the CREDENCE (n = 164 703), DAPA-CKD (n = 504 975) and EMPA-KIDNEY (n = 475 282) trials, over one-third were not prescribed a renin–angiotensin system (RAS) inhibitor [37.8% (n = 62 183), 56.1% (n = 283 316) and 59.6% (n = 283 316), respectively].